FDA Approval for Provention Bio (PRVB).

Re-cork the Champagne! We were contemplating (dreaming) about an opening price over $12, and then a drift up...

Adding Ardelyx (ARDX) $1.57 to Watch List.

FDA Advisory Committee Says Go Forth Young Man! While we hadn't previously owned Ardelyx, nor are they a...

Provention Biosciences (PRVB) Enters the Danger Zone.

Chart Looks Beautiful - But Nervous is why, we use soft and dry. LIVE QUOTE We'll...

Revive Therapeutics (RVVTF) Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

TORONTO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...

Revive (RVVTF) Hits a Snag?

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 First our summary."FDA provided communication that...

Revive Therapeutics (RVVTF) Annual Shareholder Meeting.

ANNUAL SHAREHOLDER MEETING https://vimeo.com/752050831

Adding Progressive Care (RXMD) $0.04 to Watch List.

Adding to Biotech Stock Review 2022 Watch List. Speculative, Yes. But Pay Down of $2 Million Toxic Note and...

Provention Bio (PRVB) Announces $125 Million Term Loan Facility with Hercules Capital

Don't think we've ever seen anything like this before. Most investors who prefer to invest post FDA approval, invest post FDA approval....
Dr John Fahy UCSF

Revive Therapeutics (RVVTF) Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...

Revive Therapeutics (RVVTF) Enters the Danger Zone.

What Danger You Ask? Danger #1, the FDA doesn't like the data, and you own the stock.

Latest article

Society Pass (SOPA) $1.15 Breaks Above First Line of Resistance.

If you're familiar with the term, "..the stars are aligning" here is a real life example. If you're familiar with the term,...

Silo Pharma (SILO) $2.67 Announces $1 Million Stock Buyback.

Yes it doesn't sound like a lot of money on the surface. But the stock is so grossly undervalued (in our opinion)...

Three That Doubled, Three More That May Double.

Ardelyx $3.00 (ARDX) Gains 117%, Provention Bio $8.75 (PRVB) Gains 134%, and PharmaTher (PHRRF) up 154%. Blue Skies Ahead - For All...